BioPharmSignal logoBioPharmSignal

Biotech News

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

PLUS THERAPEUTICS, Inc. (PSTV)PLUS THERAPEUTICS, Inc.Commercial

Health economics and reimbursement expert brings over two decades of experience in payer strategy, value-based pricing, and health policy supporting CNSide adoption and long-term commercialization strategy for REYOBIQ™ HOUSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc.

Related news

KURAKura Oncology2026-09-08 11:00 EST

Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer

REPLReplimune Group2026-10-01 20:01 EST

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

SNDXSyndax Pharmaceuticals2026-09-01 11:00 EST

Syndax Announces Participation in September Investor Conferences

REPLReplimune Group2026-08-19 20:01 EST

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FATEFate Therapeutics2026-09-25 11:00 EST

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

TEVATeva Pharmaceutical Industries2026-07-29 11:00 EST

Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy

NRIXNurix Therapeutics2026-10-05 11:00 EST

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

FATEFate Therapeutics2026-10-02 11:00 EST

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

View all latest news

PLUS THERAPEUTICS, Inc.

PLUS Therapeutics is an oncology company focused on radiotherapeutics and targeted treatment delivery for cancer. Its story is built around the use of radiation-based approaches to address hard-to-treat tumors.

Recent company news

PSTVPLUS THERAPEUTICS, Inc.2026-06-04 11:30 EST

Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory

PSTVPLUS THERAPEUTICS, Inc.2026-05-26 11:30 EST

Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases

PSTVPLUS THERAPEUTICS, Inc.2026-05-19 11:30 EST

Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology

PSTVPLUS THERAPEUTICS, Inc.2026-05-15 20:05 EST

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

PSTVPLUS THERAPEUTICS, Inc.2026-05-08 11:30 EST

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

Stock data

Close
3.87 USD
Market cap
37.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States